$1.25
+0.42 (+50.11%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where VCNX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
7 interventional
Held by 0 tracked-famous managers · FINRA short interest 2.9 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Trial of Immunotherapy With Avelumab and Pepinemab As Second Line For Patients With Metastatic Pancreatic AdenocarcinomaNCT05102721Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]Open-label · Treatment | Phase 1/2 | Active, not recruiting | Drug: Avelumab and Pepinemab | Metastatic Pancreatic Adenocarcinoma | 48 | 2028-12-31 | in 865 d | 2025-05-21 |
| Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckNCT04815720Number of Subjects with Treatment Emergent Adverse Events (TEAE's).Open-label · Treatment | Phase 1/2 | Completed | Drug: pepinemab + pembrolizumab | Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC) | 49 | 2024-07-24actual | — | 2025-01-08 |
| SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD)NCT04381468Number of subjects with treatment emergent adverse events (TEAEs)Randomized · Quadruple-masked · Treatment | Phase 1/2 | Completed | Drug: Pepinemab, Placebo | Alzheimer Disease | 50 | 2024-06-05actual | — | 2024-08-22 |
| VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung CancerNCT03268057Dose Escalation Phase: Number of subjects with dose-limiting toxicities (DLT)s at each dose levelOpen-label · Treatment | Phase 1/2 | Completed | Drug: VX15/2503 + avelumab | Carcinoma, Non-Small-Cell Lung | 62 | 2020-09-09actual | — | 2022-05-02 |
| A Study in Subjects With Late Prodromal & Early Manifest HD to Assess the Safety, Tolerability, pk, and Efficacy of PepiNCT02481674Revisions to SAP were made prior to un-blinding, on June 30, 2020, upon consultation with FDA.Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: VX15/2503, Placebo | Huntington's Disease | 301 | Aug 2020actual | — | 2022-05-02 |
| Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MSNCT01764737Safety/Tolerability as determined by number of patients with adverse eventsRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: VX15/2503, Placebo | Multiple Sclerosis | 50 | Nov 2014actual | — | 2015-02-06 |
| Evaluation of Safety, Tolerability, PK & PD of Intravenous VX15/2503 in Patients With Advanced Solid TumorsNCT01313065Safety/tolerability as measured by number of patients with adverse eventsOpen-label · Treatment | Phase 1 | Completed | Drug: VX15/2503 | Solid Tumors | 42 | Jun 2014actual | — | 2014-08-13 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19